<SEC-DOCUMENT>0001628280-22-027812.txt : 20221102
<SEC-HEADER>0001628280-22-027812.hdr.sgml : 20221102
<ACCEPTANCE-DATETIME>20221102160826
ACCESSION NUMBER:		0001628280-22-027812
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20221102
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20221102
DATE AS OF CHANGE:		20221102

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Vanda Pharmaceuticals Inc.
		CENTRAL INDEX KEY:			0001347178
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				030491827
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-34186
		FILM NUMBER:		221354083

	BUSINESS ADDRESS:	
		STREET 1:		2200 PENNSYLVANIA AVE NW
		STREET 2:		SUITE 300E
		CITY:			WASHINGTON
		STATE:			DC
		ZIP:			20037
		BUSINESS PHONE:		202-734-3400

	MAIL ADDRESS:	
		STREET 1:		2200 PENNSYLVANIA AVE NW
		STREET 2:		SUITE 300E
		CITY:			WASHINGTON
		STATE:			DC
		ZIP:			20037
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>vnda-20221102.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:d1366450-fae4-4bd3-a1b6-405448f6289a,g:badb3974-69b0-4ba8-88a0-09bd6d0e7b85,d:6ada4c775dbe4445b68791dbfb8dd92f--><html xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>vnda-20221102</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i55a4437699c64486a93ad70857fc2bf4_D20221102-20221102" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjZhZGE0Yzc3NWRiZTQ0NDViNjg3OTFkYmZiOGRkOTJmL3NlYzo2YWRhNGM3NzVkYmU0NDQ1YjY4NzkxZGJmYjhkZDkyZl80L2ZyYWc6ZTAxM2MxZDE2NTE0NGVkOWIxNDlhOWVmMjg3MWQ1NjYvdGFibGU6MWM5MTU1MGE0N2Y3NDQ4OGFmODE5ZDUxN2ZkYWI2ZTQvdGFibGVyYW5nZToxYzkxNTUwYTQ3Zjc0NDg4YWY4MTlkNTE3ZmRhYjZlNF8yLTEtMS0xLTQyOTA2_d468cffe-3ad9-4c3e-8df6-6b9f2df28d94">0001347178</ix:nonNumeric><ix:nonNumeric contextRef="i55a4437699c64486a93ad70857fc2bf4_D20221102-20221102" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjZhZGE0Yzc3NWRiZTQ0NDViNjg3OTFkYmZiOGRkOTJmL3NlYzo2YWRhNGM3NzVkYmU0NDQ1YjY4NzkxZGJmYjhkZDkyZl80L2ZyYWc6ZTAxM2MxZDE2NTE0NGVkOWIxNDlhOWVmMjg3MWQ1NjYvdGFibGU6MWM5MTU1MGE0N2Y3NDQ4OGFmODE5ZDUxN2ZkYWI2ZTQvdGFibGVyYW5nZToxYzkxNTUwYTQ3Zjc0NDg4YWY4MTlkNTE3ZmRhYjZlNF8zLTEtMS0xLTQyOTA2_4192f358-beaa-4c18-a0cb-4c0b1c033740">FALSE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="vnda-20221102.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i55a4437699c64486a93ad70857fc2bf4_D20221102-20221102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-02</xbrli:startDate><xbrli:endDate>2022-11-02</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i6ada4c775dbe4445b68791dbfb8dd92f_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:25.292%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM&#160;<ix:nonNumeric contextRef="i55a4437699c64486a93ad70857fc2bf4_D20221102-20221102" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjZhZGE0Yzc3NWRiZTQ0NDViNjg3OTFkYmZiOGRkOTJmL3NlYzo2YWRhNGM3NzVkYmU0NDQ1YjY4NzkxZGJmYjhkZDkyZl8xL2ZyYWc6MTdkYjhhNDNjNzIyNDM5YTkwM2YwZWE1ZDBlZTliNDYvdGV4dHJlZ2lvbjoxN2RiOGE0M2M3MjI0MzlhOTAzZjBlYTVkMGVlOWI0Nl8xMzEy_076364d8-0857-4df4-b30e-62f224b2b871">8-K</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:25.292%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pursuant to Section&#160;13 or 15(d) </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">of the Securities Exchange Act of 1934</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Date of Report (Date of earliest event reported): <ix:nonNumeric contextRef="i55a4437699c64486a93ad70857fc2bf4_D20221102-20221102" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjZhZGE0Yzc3NWRiZTQ0NDViNjg3OTFkYmZiOGRkOTJmL3NlYzo2YWRhNGM3NzVkYmU0NDQ1YjY4NzkxZGJmYjhkZDkyZl8xL2ZyYWc6MTdkYjhhNDNjNzIyNDM5YTkwM2YwZWE1ZDBlZTliNDYvdGV4dHJlZ2lvbjoxN2RiOGE0M2M3MjI0MzlhOTAzZjBlYTVkMGVlOWI0Nl8yMzM_664cc677-b6e1-433c-a569-a0ee8bebc375">November&#160;2, 2022</ix:nonNumeric> </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:25.292%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i55a4437699c64486a93ad70857fc2bf4_D20221102-20221102" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjZhZGE0Yzc3NWRiZTQ0NDViNjg3OTFkYmZiOGRkOTJmL3NlYzo2YWRhNGM3NzVkYmU0NDQ1YjY4NzkxZGJmYjhkZDkyZl8xL2ZyYWc6MTdkYjhhNDNjNzIyNDM5YTkwM2YwZWE1ZDBlZTliNDYvdGV4dHJlZ2lvbjoxN2RiOGE0M2M3MjI0MzlhOTAzZjBlYTVkMGVlOWI0Nl8xMzA1_7887b672-b28c-49c8-81d0-e933c6b107b1">VANDA PHARMACEUTICALS INC.</ix:nonNumeric></span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact name of Registrant as specified in its charter)</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:25.292%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"></td><td style="width:34.212%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.058%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.214%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i55a4437699c64486a93ad70857fc2bf4_D20221102-20221102" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjZhZGE0Yzc3NWRiZTQ0NDViNjg3OTFkYmZiOGRkOTJmL3NlYzo2YWRhNGM3NzVkYmU0NDQ1YjY4NzkxZGJmYjhkZDkyZl8xL2ZyYWc6MTdkYjhhNDNjNzIyNDM5YTkwM2YwZWE1ZDBlZTliNDYvdGFibGU6MDhiYThlMDc1ZmI0NDAzYmJlMTdhNjZjYTg1N2UwZWYvdGFibGVyYW5nZTowOGJhOGUwNzVmYjQ0MDNiYmUxN2E2NmNhODU3ZTBlZl8wLTAtMS0xLTQyOTA2_b5093353-3e29-4a69-8e68-17ecb12d4855">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i55a4437699c64486a93ad70857fc2bf4_D20221102-20221102" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjZhZGE0Yzc3NWRiZTQ0NDViNjg3OTFkYmZiOGRkOTJmL3NlYzo2YWRhNGM3NzVkYmU0NDQ1YjY4NzkxZGJmYjhkZDkyZl8xL2ZyYWc6MTdkYjhhNDNjNzIyNDM5YTkwM2YwZWE1ZDBlZTliNDYvdGFibGU6MDhiYThlMDc1ZmI0NDAzYmJlMTdhNjZjYTg1N2UwZWYvdGFibGVyYW5nZTowOGJhOGUwNzVmYjQ0MDNiYmUxN2E2NmNhODU3ZTBlZl8wLTItMS0xLTQyOTA2_edd4a516-d39f-4628-bed3-e68dd9e5bd13">001-34186</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i55a4437699c64486a93ad70857fc2bf4_D20221102-20221102" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjZhZGE0Yzc3NWRiZTQ0NDViNjg3OTFkYmZiOGRkOTJmL3NlYzo2YWRhNGM3NzVkYmU0NDQ1YjY4NzkxZGJmYjhkZDkyZl8xL2ZyYWc6MTdkYjhhNDNjNzIyNDM5YTkwM2YwZWE1ZDBlZTliNDYvdGFibGU6MDhiYThlMDc1ZmI0NDAzYmJlMTdhNjZjYTg1N2UwZWYvdGFibGVyYW5nZTowOGJhOGUwNzVmYjQ0MDNiYmUxN2E2NmNhODU3ZTBlZl8wLTQtMS0xLTQyOTA2_3b13b24b-9cee-4f48-98b6-75a0fe989d57">03-0491827</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or other jurisdiction of incorporation)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Commission File No.)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(IRS Employer Identification No.)</span></td></tr></table></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i55a4437699c64486a93ad70857fc2bf4_D20221102-20221102" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjZhZGE0Yzc3NWRiZTQ0NDViNjg3OTFkYmZiOGRkOTJmL3NlYzo2YWRhNGM3NzVkYmU0NDQ1YjY4NzkxZGJmYjhkZDkyZl8xL2ZyYWc6MTdkYjhhNDNjNzIyNDM5YTkwM2YwZWE1ZDBlZTliNDYvdGV4dHJlZ2lvbjoxN2RiOGE0M2M3MjI0MzlhOTAzZjBlYTVkMGVlOWI0Nl8xMzA2_ffc2923d-0a96-4be3-8573-29f4ab734036">2200 Pennsylvania Avenue NW</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i55a4437699c64486a93ad70857fc2bf4_D20221102-20221102" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOjZhZGE0Yzc3NWRiZTQ0NDViNjg3OTFkYmZiOGRkOTJmL3NlYzo2YWRhNGM3NzVkYmU0NDQ1YjY4NzkxZGJmYjhkZDkyZl8xL2ZyYWc6MTdkYjhhNDNjNzIyNDM5YTkwM2YwZWE1ZDBlZTliNDYvdGV4dHJlZ2lvbjoxN2RiOGE0M2M3MjI0MzlhOTAzZjBlYTVkMGVlOWI0Nl8xMzA3_691b3879-c7c8-4c47-8c5b-dcd4f29273fe">Suite 300E</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i55a4437699c64486a93ad70857fc2bf4_D20221102-20221102" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjZhZGE0Yzc3NWRiZTQ0NDViNjg3OTFkYmZiOGRkOTJmL3NlYzo2YWRhNGM3NzVkYmU0NDQ1YjY4NzkxZGJmYjhkZDkyZl8xL2ZyYWc6MTdkYjhhNDNjNzIyNDM5YTkwM2YwZWE1ZDBlZTliNDYvdGV4dHJlZ2lvbjoxN2RiOGE0M2M3MjI0MzlhOTAzZjBlYTVkMGVlOWI0Nl8xMzA4_72f2c2af-b973-416a-890e-41c6ae3cf284">Washington</ix:nonNumeric>, <ix:nonNumeric contextRef="i55a4437699c64486a93ad70857fc2bf4_D20221102-20221102" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjZhZGE0Yzc3NWRiZTQ0NDViNjg3OTFkYmZiOGRkOTJmL3NlYzo2YWRhNGM3NzVkYmU0NDQ1YjY4NzkxZGJmYjhkZDkyZl8xL2ZyYWc6MTdkYjhhNDNjNzIyNDM5YTkwM2YwZWE1ZDBlZTliNDYvdGV4dHJlZ2lvbjoxN2RiOGE0M2M3MjI0MzlhOTAzZjBlYTVkMGVlOWI0Nl8xMzA5_db53dd2d-2eaa-4a9b-b587-5e882308478b">DC</ix:nonNumeric> <ix:nonNumeric contextRef="i55a4437699c64486a93ad70857fc2bf4_D20221102-20221102" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjZhZGE0Yzc3NWRiZTQ0NDViNjg3OTFkYmZiOGRkOTJmL3NlYzo2YWRhNGM3NzVkYmU0NDQ1YjY4NzkxZGJmYjhkZDkyZl8xL2ZyYWc6MTdkYjhhNDNjNzIyNDM5YTkwM2YwZWE1ZDBlZTliNDYvdGV4dHJlZ2lvbjoxN2RiOGE0M2M3MjI0MzlhOTAzZjBlYTVkMGVlOWI0Nl8zNzk_89f5ab37-d9a9-4e00-8bac-1473e5a7e6ef">20037</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Address of principal executive offices and zip code)</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Registrant&#8217;s telephone number, including area code: (<ix:nonNumeric contextRef="i55a4437699c64486a93ad70857fc2bf4_D20221102-20221102" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjZhZGE0Yzc3NWRiZTQ0NDViNjg3OTFkYmZiOGRkOTJmL3NlYzo2YWRhNGM3NzVkYmU0NDQ1YjY4NzkxZGJmYjhkZDkyZl8xL2ZyYWc6MTdkYjhhNDNjNzIyNDM5YTkwM2YwZWE1ZDBlZTliNDYvdGV4dHJlZ2lvbjoxN2RiOGE0M2M3MjI0MzlhOTAzZjBlYTVkMGVlOWI0Nl80ODk_ec439f44-5e00-448e-b2d4-1c46a1f2224e">202</ix:nonNumeric>) <ix:nonNumeric contextRef="i55a4437699c64486a93ad70857fc2bf4_D20221102-20221102" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjZhZGE0Yzc3NWRiZTQ0NDViNjg3OTFkYmZiOGRkOTJmL3NlYzo2YWRhNGM3NzVkYmU0NDQ1YjY4NzkxZGJmYjhkZDkyZl8xL2ZyYWc6MTdkYjhhNDNjNzIyNDM5YTkwM2YwZWE1ZDBlZTliNDYvdGV4dHJlZ2lvbjoxN2RiOGE0M2M3MjI0MzlhOTAzZjBlYTVkMGVlOWI0Nl8xMzEw_434ce63e-dc4e-4dfe-951b-c32812917c8a">734-3400</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Not Applicable</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Former Name or Former Address, if Changed Since Last Report)</span></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:25.292%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Check the appropriate box below if the Form&#160;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:0.1%"></td><td style="width:2.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.972%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i55a4437699c64486a93ad70857fc2bf4_D20221102-20221102" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjZhZGE0Yzc3NWRiZTQ0NDViNjg3OTFkYmZiOGRkOTJmL3NlYzo2YWRhNGM3NzVkYmU0NDQ1YjY4NzkxZGJmYjhkZDkyZl8xL2ZyYWc6MTdkYjhhNDNjNzIyNDM5YTkwM2YwZWE1ZDBlZTliNDYvdGFibGU6NDgzMTMxZTNhMjBkNDc2MmIxY2UzYWJjOGY1YTE1OGIvdGFibGVyYW5nZTo0ODMxMzFlM2EyMGQ0NzYyYjFjZTNhYmM4ZjVhMTU4Yl8wLTAtMS0xLTQyOTA2_f4968d31-bcef-43c5-9b59-c6e11ffc9cd9">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i55a4437699c64486a93ad70857fc2bf4_D20221102-20221102" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjZhZGE0Yzc3NWRiZTQ0NDViNjg3OTFkYmZiOGRkOTJmL3NlYzo2YWRhNGM3NzVkYmU0NDQ1YjY4NzkxZGJmYjhkZDkyZl8xL2ZyYWc6MTdkYjhhNDNjNzIyNDM5YTkwM2YwZWE1ZDBlZTliNDYvdGFibGU6NDgzMTMxZTNhMjBkNDc2MmIxY2UzYWJjOGY1YTE1OGIvdGFibGVyYW5nZTo0ODMxMzFlM2EyMGQ0NzYyYjFjZTNhYmM4ZjVhMTU4Yl8yLTAtMS0xLTQyOTA2_2c058764-68ca-4017-aca4-f93962c9567e">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i55a4437699c64486a93ad70857fc2bf4_D20221102-20221102" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjZhZGE0Yzc3NWRiZTQ0NDViNjg3OTFkYmZiOGRkOTJmL3NlYzo2YWRhNGM3NzVkYmU0NDQ1YjY4NzkxZGJmYjhkZDkyZl8xL2ZyYWc6MTdkYjhhNDNjNzIyNDM5YTkwM2YwZWE1ZDBlZTliNDYvdGFibGU6NDgzMTMxZTNhMjBkNDc2MmIxY2UzYWJjOGY1YTE1OGIvdGFibGVyYW5nZTo0ODMxMzFlM2EyMGQ0NzYyYjFjZTNhYmM4ZjVhMTU4Yl80LTAtMS0xLTQyOTA2_f884c670-d45a-43b4-b1b8-d860cb8c4974">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule&#160;14d-2(b)&#160;under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i55a4437699c64486a93ad70857fc2bf4_D20221102-20221102" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjZhZGE0Yzc3NWRiZTQ0NDViNjg3OTFkYmZiOGRkOTJmL3NlYzo2YWRhNGM3NzVkYmU0NDQ1YjY4NzkxZGJmYjhkZDkyZl8xL2ZyYWc6MTdkYjhhNDNjNzIyNDM5YTkwM2YwZWE1ZDBlZTliNDYvdGFibGU6NDgzMTMxZTNhMjBkNDc2MmIxY2UzYWJjOGY1YTE1OGIvdGFibGVyYW5nZTo0ODMxMzFlM2EyMGQ0NzYyYjFjZTNhYmM4ZjVhMTU4Yl82LTAtMS0xLTQyOTA2_eccdcbf8-fe0c-4212-a0c7-e6db74af7bf3">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule&#160;13e-4(c)&#160;under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div style="margin-top:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:35.942%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.815%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.943%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Trading Symbol</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i55a4437699c64486a93ad70857fc2bf4_D20221102-20221102" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjZhZGE0Yzc3NWRiZTQ0NDViNjg3OTFkYmZiOGRkOTJmL3NlYzo2YWRhNGM3NzVkYmU0NDQ1YjY4NzkxZGJmYjhkZDkyZl8xL2ZyYWc6MTdkYjhhNDNjNzIyNDM5YTkwM2YwZWE1ZDBlZTliNDYvdGFibGU6MmNmZTMxMTVjN2FjNDk4MGIxNmM3NjMxZjI2ZjU3OWMvdGFibGVyYW5nZToyY2ZlMzExNWM3YWM0OTgwYjE2Yzc2MzFmMjZmNTc5Y18xLTAtMS0xLTQyOTA2_f64059cf-8c2a-47f4-906c-be49a6bd067b">Common Stock, par value $0.001 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i55a4437699c64486a93ad70857fc2bf4_D20221102-20221102" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjZhZGE0Yzc3NWRiZTQ0NDViNjg3OTFkYmZiOGRkOTJmL3NlYzo2YWRhNGM3NzVkYmU0NDQ1YjY4NzkxZGJmYjhkZDkyZl8xL2ZyYWc6MTdkYjhhNDNjNzIyNDM5YTkwM2YwZWE1ZDBlZTliNDYvdGFibGU6MmNmZTMxMTVjN2FjNDk4MGIxNmM3NjMxZjI2ZjU3OWMvdGFibGVyYW5nZToyY2ZlMzExNWM3YWM0OTgwYjE2Yzc2MzFmMjZmNTc5Y18xLTEtMS0xLTQyOTA2_85768338-3c23-419b-a9d2-3fff31ad26e5">VNDA</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i55a4437699c64486a93ad70857fc2bf4_D20221102-20221102" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjZhZGE0Yzc3NWRiZTQ0NDViNjg3OTFkYmZiOGRkOTJmL3NlYzo2YWRhNGM3NzVkYmU0NDQ1YjY4NzkxZGJmYjhkZDkyZl8xL2ZyYWc6MTdkYjhhNDNjNzIyNDM5YTkwM2YwZWE1ZDBlZTliNDYvdGFibGU6MmNmZTMxMTVjN2FjNDk4MGIxNmM3NjMxZjI2ZjU3OWMvdGFibGVyYW5nZToyY2ZlMzExNWM3YWM0OTgwYjE2Yzc2MzFmMjZmNTc5Y18xLTItMS0xLTQyOTA2_a372827c-11d1-4687-b35f-7a3cc4c377eb">The Nasdaq Global Market</ix:nonNumeric></span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule&#160;405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule&#160;12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i55a4437699c64486a93ad70857fc2bf4_D20221102-20221102" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjZhZGE0Yzc3NWRiZTQ0NDViNjg3OTFkYmZiOGRkOTJmL3NlYzo2YWRhNGM3NzVkYmU0NDQ1YjY4NzkxZGJmYjhkZDkyZl8xL2ZyYWc6MTdkYjhhNDNjNzIyNDM5YTkwM2YwZWE1ZDBlZTliNDYvdGV4dHJlZ2lvbjoxN2RiOGE0M2M3MjI0MzlhOTAzZjBlYTVkMGVlOWI0Nl8xMzEz_0a4b47ee-bcd7-490a-9afa-1a2c79a67e6b">&#9744;</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act.&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#168;</span></div><div style="margin-bottom:1pt;margin-top:4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="i6ada4c775dbe4445b68791dbfb8dd92f_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;margin-top:4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:8.430%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.637%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;2.02.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Results of Operations and Financial Condition.</span></td></tr></table></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November&#160;2, 2022, Vanda Pharmaceuticals Inc. (&#8220;Vanda&#8221;) issued a press release and is holding a conference call regarding its results of operations and financial condition for the quarter ended September 30, 2022. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Various statements to be made during the conference call are &#8220;forward-looking statements&#8221; under the securities laws, including, but not limited to, Vanda&#8217;s financial guidance for 2022, and statements regarding Vanda&#8217;s commercial products, plans and opportunities, as well as statements about Vanda&#8217;s products in development and the related clinical development and regulatory timelines and commercial potential for such products. Words such as, but not limited to, &#8220;believe,&#8221; &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;estimate,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;project,&#8221; &#8220;target,&#8221; &#8220;goal,&#8221; &#8220;likely,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; and &#8220;could,&#8221; or the negative of these terms and similar expressions or words, identify forward-looking statements. Forward-looking statements are based upon current expectations and assumptions that involve risks, changes in circumstances and uncertainties.  </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Important factors that could cause actual results to differ materially from those reflected in Vanda&#8217;s forward-looking statements include, among others, Vanda&#8217;s assumptions regarding the strength of its business in the U.S. and Vanda&#8217;s ability to complete the clinical development of, and obtain regulatory approval for, the products in its pipeline. Therefore, no assurance can be given that the actual results or developments anticipated by Vanda will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Vanda. Forward-looking statements made during the call should be evaluated together with the various risks and uncertainties that affect Vanda&#8217;s business and market, particularly those identified in the &#8220;Cautionary Note Regarding Forward-Looking Statements&#8221;, &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; sections of Vanda&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2021, as updated by Vanda&#8217;s subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All written and verbal forward-looking statements attributable to Vanda or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements contained or referred to herein. The information contained in this Current Report on Form 8-K is intended to be considered in the context of Vanda&#8217;s filings with the SEC and other public announcements that Vanda makes, by press release or otherwise, from time to time. Vanda cautions investors not to rely too heavily on the forward-looking statements Vanda makes or that are made on its behalf. The information conveyed on the conference call will be provided only as of the date of the call, and Vanda undertakes no obligation, and specifically declines any obligation, to update or revise publicly any forward-looking statements made during the call after the date thereof, whether as a result of new information, future events or otherwise, except as required by law.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information in Item 2.02 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:8.430%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.637%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;9.01.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Statements and Exhibits.</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:22.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.84pt">Exhibits</span></div><div style="text-indent:9pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:82.918%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit&#160;No.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td></tr><tr style="height:8pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="vnda8-k1122022exhibit991.htm">Press release of Vanda Pharmaceuticals Inc. dated November 2, 2022.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (embedded within the Inline XBRL document).</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="i6ada4c775dbe4445b68791dbfb8dd92f_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="margin-top:6pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:5.399%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.839%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.069%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.024%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.431%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VANDA PHARMACEUTICALS INC.</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Timothy Williams</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Timothy Williams</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President, General Counsel and Secretary</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>vnda8-k1122022exhibit991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i0e4cbf3b71d14b94976aab481e18c525_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font><img alt="vandaq32019earningsca_imaga.jpg" src="vandaq32019earningsca_imaga.jpg" style="height:88px;margin-bottom:5pt;vertical-align:text-bottom;width:264px"></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Vanda Pharmaceuticals Reports Third Quarter 2022 Financial Results</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:6pt;margin-top:18pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Q3 2022 total revenues were $65.3 million</font></div><div style="margin-bottom:6pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Total revenues in the first nine months of 2022 were $189.9 million</font></div><div style="margin-bottom:6pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Vanda provides update on pipeline advancements and upcoming milestones </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">WASHINGTON</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; November&#160;2, 2022 &#8211; Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq&#58; VNDA) today announced financial and operational results for the third quarter ended September 30, 2022.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#8220;We continue to focus on strong commercial execution, the advancement of our clinical pipeline and our upcoming regulatory milestones of the submissions of an NDA for tradipitant in gastroparesis and an sNDA for HETLIOZ</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:107%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> in insomnia,&#8221; said Mihael H. Polymeropoulos, M.D., Vanda&#8217;s President, CEO and Chairman of the Board. &#8220;With stable, mature revenue, efficient operations and strong cash on hand, we are well positioned to deliver long-term growth.&#8221;</font></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Highlights</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Third Quarter of 2022</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Total net product sales from HETLIOZ</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Fanapt</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> were $65.3 million in the third quarter of 2022, a 7% decrease compared to $70.1 million in the third quarter of 2021.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">HETLIOZ</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> net product sales were $41.3 million in the third quarter of 2022, a 9% decrease compared to $45.6 million in the third quarter of 2021, due in part to continued reimbursement challenges for prescriptions for patients with Non-24.</font></div><div><font><br></font></div><div style="padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Fanapt</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> net product sales were $24.0 million in the third quarter of 2022, a 2% decrease compared to $24.5 million in the third quarter of 2021.</font></div><div><font><br></font></div><div style="padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Net income was $3.3 million in the third quarter of 2022 compared to $7.8 million in the third quarter of 2021.</font></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Cash, cash equivalents and marketable securities (Cash) was $454.8 million as of September 30, 2022, representing an increase to Cash of $13.9 million, or 3%, compared to June 30, 2022.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">First Nine Months of 2022</font></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Total net product sales from HETLIOZ</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Fanapt</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> were $189.9 million in the first nine months of 2022, a 5% decrease compared to $200.7 million in the first nine months of 2021.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">HETLIOZ</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> net product sales were $119.6 million in the first nine months of 2022, an 8% decrease compared to $129.5 million in the first nine months of 2021, due in part to continued reimbursement challenges for prescriptions for patients with Non-24.</font></div><div><font><br></font></div><div style="padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Fanapt</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> net product sales were $70.3 million in the first nine months of 2022, a 1% decrease compared to $71.2 million in the first nine months of 2021.</font></div><div><font><br></font></div><div style="padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Net loss was $0.6 million in the first nine months of 2022 compared to net income of $26.1 million in the first nine months of 2021.</font></div><div><font><br></font></div><div style="padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Cash, cash equivalents and marketable securities (Cash) was $454.8 million as of September 30, 2022, representing an increase to Cash of $48.8 million, or 12%, compared to September 30, 2021.</font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:right"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Key Operational Highlights </font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">HETLIOZ</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;text-decoration:underline;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"> (tasimelteon)</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Vanda is preparing for the submission of a supplemental New Drug Application (sNDA) for HETLIOZ</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the treatment of insomnia. Vanda expects to submit this sNDA to the U.S. Food and Drug Administration (FDA) by the end of 2022.</font></div><div style="margin-top:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Tradipitant</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Vanda is continuing to conduct an open-label safety study for tradipitant in gastroparesis and continues to receive requests from patients seeking access to tradipitant through the Expanded Access program that has multiple patients who have taken tradipitant for more than a year.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Vanda is preparing for the submission of a New Drug Application (NDA) for tradipitant in the short-term treatment of nausea in gastroparesis. Vanda expects to submit this NDA to the FDA in the first half of 2023.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Phase III study of tradipitant in the treatment of motion sickness is approximately 40% enrolled. Results are expected by mid-2023.</font></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Fanapt</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;text-decoration:underline;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"> (iloperidone)</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Enrollment of the Phase III clinical study of Fanapt</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in acute manic episodes in patients with bipolar I disorder is fully enrolled. The study is a placebo controlled four-week evaluation of approximately 400 patients at sites in the U.S. and Europe. Results are expected by the end of 2022.</font></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Early-Stage Programs</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Phase II clinical study of a single-dose treatment of VQW-765 to alleviate social&#47;performance anxiety is fully enrolled. Results are expected by the end of 2022.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In September 2022, Vanda and OliPass Corporation (OliPass) announced a research and development agreement to jointly develop a set of antisense oligonucleotide (ASO) molecules based on OliPass&#8217; proprietary modified peptide nucleic acids. Vanda has already identified two ASO targets that have been validated in cell lines that model two disease targets, one rare orphan and the other applicable to a broad set of immuno-oncological conditions.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In October 2022, Vanda announced that the FDA has granted Orphan Drug Designation for VPO-227 (formerly BPO-27) for the treatment of cholera. Vanda expects to submit an Investigational New Drug (IND) application to the FDA for VPO-227 in 2023.</font></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Legal and Regulatory Updates</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The decision for the consolidated HETLIOZ</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> patent lawsuit against Abbreviated New Drug Application (ANDA) defendants is expected from the court by the end of 2022.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Vanda&#8217;s lawsuit against the Centers for Medicare &#38; Medicaid Services (CMS) is currently pending and challenges a CMS rule that subjects certain of Vanda&#8217;s products to enhanced rebates. Vanda believes the rule is unlawful and contrary to the intent of Congress when it passed the Affordable Care Act.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Vanda filed a lawsuit against the FDA on September 13, 2022 demanding that the FDA immediately publish in the Federal Register a notice of opportunity for a hearing on Vanda&#8217;s sNDA for HETLIOZ</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the treatment of Jet Lag Disorder. The FDA then published the notice in the Federal Register on October 11, 2022. Vanda intends to continue pursuing FDA approval of the sNDA for HETLIOZ</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the treatment of Jet Lag Disorder.</font></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GAAP Financial Results</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income was $3.3 million in the third quarter of 2022 compared to net income of $7.8 million in the third quarter of 2021. Diluted net income per share was $0.06 in the third quarter of 2022 compared to diluted net income per share of $0.14 in the third quarter of 2021.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss was $0.6 million in the first nine months of 2022 compared to net income of $26.1 million in the first nine months of 2021. Diluted net loss per share was $0.01 in the first nine months of 2022 compared to diluted net income per share of $0.46 in the first nine months of 2021.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:right"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022 Financial Guidance </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vanda is updating its 2022 financial guidance and expects to achieve the following financial objectives in 2022</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#58;</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Full Year 2022</font></div><div style="padding-left:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial Objectives</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revised Full Year 2022</font></div><div style="padding-left:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Guidance</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior Full Year 2022</font></div><div style="padding-left:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Guidance</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$240 to $270 million</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$240 to $280 million</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HETLIOZ</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> net product sales</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$150 to $170 million</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$150 to $180 million</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fanapt</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> net product sales</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$90 to $100 million</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$90 to $100 million</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year-end 2022 Cash</font></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Greater than $450 million</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Greater than $440 million</font></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Conference Call</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vanda has scheduled a conference call for today, Wednesday, November&#160;2, 2022, at 4&#58;30 PM ET. During the call, Vanda&#8217;s management will discuss the third quarter 2022 financial results and other corporate activities. Investors can call 1-800-715-9871 (domestic) or 1-646-307-1963 (international) and use passcode number 5456289. A replay of the call will be available on Wednesday, November&#160;2, 2022, beginning at 8&#58;30 PM ET and will be accessible until Wednesday, November&#160;9, 2022 at 8&#58;30 PM ET. The replay call-in number is 1-800-770-2030 for domestic callers and 1-609-800-9909 for international callers. The passcode number is 5456289.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The conference call will be broadcast simultaneously on Vanda&#8217;s website, www.vandapharma.com. Investors should click on the Investors tab and are advised to go to the website at least 15 minutes early to register, download, and install any necessary software or presentations. The call will also be archived on Vanda&#8217;s website for a period of 30 days.</font></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">About Vanda Pharmaceuticals Inc.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com and follow us on Twitter &#64;vandapharma.</font></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">CAUTIONARY NOTE REGARDING FORWARD LOOKING STATEMENTS</font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Various statements in this press release, including, but not limited to, the guidance provided under &#8220;2022 Financial Guidance&#8221; above and statements regarding Vanda&#8217;s plans for pursuit of regulatory approval of HETLIOZ</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the treatment of insomnia and Jet Lag Disorder, and tradipitant in the short-term treatment of nausea in gastroparesis and in the treatment of motion sickness, the research and development activities of the strategic partnership between Vanda and OliPass and the potential therapeutic opportunities that may result from it, Vanda's clinical development and regulatory plans and strategies for VPO-227, the timing of the court&#8217;s decision with respect to the Company&#8217;s HETLIOZ</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> patent litigation, and the clinical development timelines for tradipitant, Fanapt</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and VQW-765 are &#8220;forward-looking statements&#8221; under the securities laws. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Forward-looking statements are based upon current expectations and assumptions that involve risks, changes in circumstances and uncertainties. Important factors that could cause actual results to differ materially from those reflected in Vanda&#8217;s forward-looking statements include, among others, Vanda&#8217;s assumptions regarding the strength of its business in the U.S., Vanda's ability to complete and submit the NDA and sNDA for tradipitant and HETLIOZ</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, respectively, in the fourth quarter of 2022 and the first half of 2023, respectively, the FDA&#8217;s assessment of the sufficiency of the data packages to be included in Vanda&#8217;s planned NDA and sNDA submissions for tradipitant and HETLIOZ</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, respectively, Vanda&#8217;s ability to complete the Phase III clinical study of tradipitant in the treatment of motion sickness by mid-2023, Vanda&#8217;s ability to complete the Phase III clinical study of Fanapt</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in bipolar I disorder in the fourth quarter of 2022, Vanda's ability to complete the Phase II clinical study of VQW-765 in social&#47;performance anxiety in the fourth quarter of 2022, Vanda ability to progress the two ASO targets it has identified, and Vanda's ability to complete the IND for VPO-227 and submit it to the FDA in 2023. Therefore, no assurance can be given that the results or developments anticipated by Vanda will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Vanda. Forward-looking statements in this press release should be evaluated together with the various risks and uncertainties that affect Vanda&#8217;s business and market, particularly those identified in the &#8220;Cautionary Note Regarding Forward-Looking Statements&#8221;, &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; sections of Vanda&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2021, as updated by Vanda&#8217;s subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the U.S. Securities and Exchange Commission, which are available at </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">www.sec.gov</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:right"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">All written and verbal forward-looking statements attributable to Vanda or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements contained or referred to herein. Vanda cautions investors not to rely too heavily on the forward-looking statements Vanda makes or that are made on its behalf. The information in this press release is provided only as of the date of this press release, and Vanda undertakes no obligation, and specifically declines any obligation, to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:right"><font><br></font></div></div></div><div id="i0e4cbf3b71d14b94976aab481e18c525_7"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">VANDA PHARMACEUTICALS INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(in thousands, except for share and per share amounts)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(unaudited)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:41.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30<br>2022</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30<br>2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30<br>2022</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30<br>2021</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues&#58;</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:20.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HETLIOZ</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> net product sales</font></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,335&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,615&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,554&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129,467&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:20.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fanapt</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> net product sales</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,983&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,480&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,346&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,196&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,318&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,095&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189,900&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,663&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold excluding amortization</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,320&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,797&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,044&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,393&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,857&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,653&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,316&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,032&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,854&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,456&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,703&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,600&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible asset amortization</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">379&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">370&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,137&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,109&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,410&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,276&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190,200&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167,134&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from operations</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,908&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,819&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(300)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,529&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense)</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,553&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(97)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,987&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,461&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,722&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,687&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,754&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,191&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,951&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,273&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,680&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,270&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,771&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(586)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,074&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per share, basic</font></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.06&#160;</font></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.14&#160;</font></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.01)</font></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.47&#160;</font></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per share, diluted</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.06&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.14&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.01)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.46&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding, basic</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,574,503&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,668,156&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,397,805&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,467,528&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding, diluted</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,969,033&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,040,736&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,397,805&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,818,295&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:right"><font><br></font></div></div></div><div id="i0e4cbf3b71d14b94976aab481e18c525_10"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">VANDA PHARMACEUTICALS INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED BALANCE SHEETS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(in thousands)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(unaudited)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:68.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.564%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30<br>2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31<br>2021</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,397&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,071&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">405,394&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">380,742&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,352&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,467&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,590&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,025&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,373&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,996&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">507,106&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">478,301&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,594&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,113&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,262&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,272&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,944&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,081&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,529&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,878&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current inventory and other</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,353&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,147&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">621,788&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">593,792&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</font></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,125&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,438&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenue allowances</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,498&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,981&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,623&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,419&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease non-current liabilities</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,903&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,055&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current liabilities</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,605&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,390&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,131&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,864&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders&#8217; equity&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:20.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">681,847&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">669,223&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,485)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(175)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(164,762)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(164,176)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">515,657&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">504,928&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">621,788&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">593,792&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:right"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Corporate Contact&#58; </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Kevin Moran</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Senior Vice President, Chief Financial Officer and Treasurer</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vanda Pharmaceuticals Inc.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">202-734-3400</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">pr&#64;vandapharma.com</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Elizabeth Van Every</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Head of Corporate Affairs</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vanda Pharmaceuticals Inc.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">202-734-3400</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">pr&#64;vandapharma.com</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SOURCE Vanda Pharmaceuticals Inc.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:right"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>vnda-20221102.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:d1366450-fae4-4bd3-a1b6-405448f6289a,g:badb3974-69b0-4ba8-88a0-09bd6d0e7b85-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:vnda="http://www.vandapharmaceuticals.com/20221102" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.vandapharmaceuticals.com/20221102">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vnda-20221102_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vnda-20221102_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.vandapharmaceuticals.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>vnda-20221102_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:d1366450-fae4-4bd3-a1b6-405448f6289a,g:badb3974-69b0-4ba8-88a0-09bd6d0e7b85-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_EntityAddressAddressLine1_6c5c36bf-3aad-480d-aad4-c8ad51cd87a9_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_1e429e94-1854-4feb-853c-599dfe992ac9_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_c5fc9752-219c-4030-a767-f574cc0ed433_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_720efe51-ac03-4be7-9061-6c5e05637194_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_4b6347c3-b5d3-45de-b4fc-a3bc526216e5_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_f22eb0ed-55c5-47df-9230-61504a091493_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_a5eac726-a2bf-4a0e-bfeb-7e290010a3f9_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_0de45aa6-dbe4-4ccb-a526-5ee7dbb1a855_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_8937d12b-f7fb-46cb-9c0b-bd80ceeab441_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_2686bfa7-8f92-43ec-b83f-c90f13f0e1bd_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_8a704f81-b425-4325-9152-a911a48748d6_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_c1c2632e-596e-4b00-99ee-17375d3ec0fd_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_208a0262-ef84-435b-983b-ca63cb1cfce0_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_4d692ae6-f3b8-4658-bf39-bbee7c399aa1_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_b5cde6a7-fd8f-41f5-9e5f-944db8bb67ff_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_b0e9f269-ebfa-4bcf-b431-07bc8eabd033_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_0c63c588-f04a-4d49-ba2e-1fb409e2dc1e_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_0da7cb05-f33c-40c6-86b1-0ba4ccd0496a_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_b95e6862-05cc-499f-9dea-6c52c92b77be_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_92ed3635-94f3-4d91-ab65-c818c61d2068_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_ba05c846-9d97-49ad-b7c9-dbed96a75c53_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_8b4329fe-e418-49f1-94a3-d34ad552b342_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_9d556cf2-613e-41ca-821d-9af646a91565_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>vnda-20221102_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:d1366450-fae4-4bd3-a1b6-405448f6289a,g:badb3974-69b0-4ba8-88a0-09bd6d0e7b85-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CoverPage" xlink:type="simple" xlink:href="vnda-20221102.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_4447dd4a-77f4-4a24-bbbb-eb1113866be2" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_45171ea6-5d33-4df9-805f-dce3f4e31f6f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4447dd4a-77f4-4a24-bbbb-eb1113866be2" xlink:to="loc_dei_DocumentType_45171ea6-5d33-4df9-805f-dce3f4e31f6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_82a36b42-1777-4672-9b44-ee7004126cb8" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4447dd4a-77f4-4a24-bbbb-eb1113866be2" xlink:to="loc_dei_EntityRegistrantName_82a36b42-1777-4672-9b44-ee7004126cb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_4256ce47-2a9d-4c7b-9002-9b673bb24bcb" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4447dd4a-77f4-4a24-bbbb-eb1113866be2" xlink:to="loc_dei_EntityIncorporationStateCountryCode_4256ce47-2a9d-4c7b-9002-9b673bb24bcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_d63ce304-d5da-42d6-998c-5013cccfaf4e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4447dd4a-77f4-4a24-bbbb-eb1113866be2" xlink:to="loc_dei_EntityFileNumber_d63ce304-d5da-42d6-998c-5013cccfaf4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_4d071a9e-ea68-4b00-9842-0dccf07abe69" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4447dd4a-77f4-4a24-bbbb-eb1113866be2" xlink:to="loc_dei_EntityTaxIdentificationNumber_4d071a9e-ea68-4b00-9842-0dccf07abe69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_30ec7a35-192d-4973-b0d4-cb1a1823354a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4447dd4a-77f4-4a24-bbbb-eb1113866be2" xlink:to="loc_dei_EntityAddressAddressLine1_30ec7a35-192d-4973-b0d4-cb1a1823354a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_275fc21a-aff1-40cb-aef5-fa233f2b2c01" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4447dd4a-77f4-4a24-bbbb-eb1113866be2" xlink:to="loc_dei_EntityAddressAddressLine2_275fc21a-aff1-40cb-aef5-fa233f2b2c01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_12676433-3e9e-4ffc-9d87-865c5c123ec4" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4447dd4a-77f4-4a24-bbbb-eb1113866be2" xlink:to="loc_dei_EntityAddressCityOrTown_12676433-3e9e-4ffc-9d87-865c5c123ec4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_a4944b53-75c8-4573-b1d1-ae3d5bb4a71b" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4447dd4a-77f4-4a24-bbbb-eb1113866be2" xlink:to="loc_dei_EntityAddressStateOrProvince_a4944b53-75c8-4573-b1d1-ae3d5bb4a71b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_28d1426d-242d-485c-9885-4743109f1380" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4447dd4a-77f4-4a24-bbbb-eb1113866be2" xlink:to="loc_dei_EntityAddressPostalZipCode_28d1426d-242d-485c-9885-4743109f1380" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_330ab97a-4dd4-47c1-b101-0498903f2662" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4447dd4a-77f4-4a24-bbbb-eb1113866be2" xlink:to="loc_dei_CityAreaCode_330ab97a-4dd4-47c1-b101-0498903f2662" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_7f3baaab-4ba4-4a9c-8a9a-4124af42e143" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4447dd4a-77f4-4a24-bbbb-eb1113866be2" xlink:to="loc_dei_LocalPhoneNumber_7f3baaab-4ba4-4a9c-8a9a-4124af42e143" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_0d89a27d-0d0c-4288-bc58-372cf5d4d326" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4447dd4a-77f4-4a24-bbbb-eb1113866be2" xlink:to="loc_dei_WrittenCommunications_0d89a27d-0d0c-4288-bc58-372cf5d4d326" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_47e91138-ff7a-49ba-931c-5b6b6847833e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4447dd4a-77f4-4a24-bbbb-eb1113866be2" xlink:to="loc_dei_SolicitingMaterial_47e91138-ff7a-49ba-931c-5b6b6847833e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_10a77e9d-e7e3-485d-ac72-73f616423a0c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4447dd4a-77f4-4a24-bbbb-eb1113866be2" xlink:to="loc_dei_PreCommencementTenderOffer_10a77e9d-e7e3-485d-ac72-73f616423a0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_7de7df16-99c2-4b4c-b524-58e0f42bb05d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4447dd4a-77f4-4a24-bbbb-eb1113866be2" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_7de7df16-99c2-4b4c-b524-58e0f42bb05d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_d0c4f069-f412-4a52-b179-f3e5bd0eb3b6" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4447dd4a-77f4-4a24-bbbb-eb1113866be2" xlink:to="loc_dei_Security12bTitle_d0c4f069-f412-4a52-b179-f3e5bd0eb3b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_17f755d8-da9e-4e6d-bb0f-e7335d758a07" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4447dd4a-77f4-4a24-bbbb-eb1113866be2" xlink:to="loc_dei_TradingSymbol_17f755d8-da9e-4e6d-bb0f-e7335d758a07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_729d33af-6746-4377-a1ef-e994185388e0" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4447dd4a-77f4-4a24-bbbb-eb1113866be2" xlink:to="loc_dei_SecurityExchangeName_729d33af-6746-4377-a1ef-e994185388e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_36b94f33-a9a5-41eb-8d09-681974b12527" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4447dd4a-77f4-4a24-bbbb-eb1113866be2" xlink:to="loc_dei_EntityEmergingGrowthCompany_36b94f33-a9a5-41eb-8d09-681974b12527" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_20bb962d-d3ee-44ac-93f9-ae0fb29db9f1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4447dd4a-77f4-4a24-bbbb-eb1113866be2" xlink:to="loc_dei_EntityCentralIndexKey_20bb962d-d3ee-44ac-93f9-ae0fb29db9f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_384c974e-def7-4c4a-9265-20e6b5054931" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4447dd4a-77f4-4a24-bbbb-eb1113866be2" xlink:to="loc_dei_AmendmentFlag_384c974e-def7-4c4a-9265-20e6b5054931" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_e97c9242-093e-4b88-aa2d-8fd5d4bef698" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4447dd4a-77f4-4a24-bbbb-eb1113866be2" xlink:to="loc_dei_DocumentPeriodEndDate_e97c9242-093e-4b88-aa2d-8fd5d4bef698" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>vandaq32019earningsca_imaga.jpg
<TEXT>
begin 644 vandaq32019earningsca_imaga.jpg
M_]C_X  02D9)1@ ! @$ 2 !(  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
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M^RO?-WL^7]FN]]W Z;&SMY)I#YZ8T+D"O$D"@'F:#IFYGCM;=[F7^SC0L?L
MKUJY[NW-D]Z;IW%N[,R>7*[FS>3SN08$E!592LFK)8X@WZ((6ET1J.%10
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MCNH:K9M5U#L[?$LN^-G9O/9K^-9[-[NQ]<JUV/W=@X!1"#!P^./PEE8L2QN
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M6FE2 :T!-:5(%<<*CSZJG[DG_E&]*YRNZ_[0^1/777^^<94+C\OA!W&,EN_
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M[^MG,O[GV]Z[%MS,BT.))N$LGH0M/#C.<!F4TDZV6/Y%W\OA/AG\7:3L3?\
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MH>NC=K=6]]:QWMFZR6DR*Z.IJK(P#*P/F""".E![9Z?ZT%/^%+7_ &\4PO\
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M9]BN7"U[8KZ-HB1Z)<Q*T4I/E^G&OJW4BV.U;'S%$;GE'<[6]C J4UC6H_I
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MTY*13T'!@/TW/^F4:"3@:4'%NLP?NV\Z>-:S\CWS_J0UGMJGBC']:,?Z5B)
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M6+41%_LIE$J^T_)G]:-_%W>I79K(AY*C#O\ Z''\P2-3C^%=)IJ'4*^]W/\
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M@:>?_"EK_MXIA?\ Q7#K3_WJ>Q_>2OL7_P J4_\ SW2_\<BZQ$^\A_T\)/\
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M-)B\I4.?1!C**KD/"^YD]D^8(-HYH;;KI@L%_&(U)P/%4ZHP3_2!=!ZLRCJ
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M%\].'8?Q:/-3U)'W=.0/IX&Y\W-/UI0T=H",A/ADF%>!?,:'CI$G%7!Z2O\
MPI!_F)A4HOY?_4^=82%L1NWY(Y/&U#*5C,=+F=C=522PS699A)#G<M$R?1<:
MBO8U47M1[(<E9/..XIC*6P/YK)+_ (8T/^G-/A/27[Q7N%0+R%M3Y[9+P@_8
MT4''SQ+(*?[[%?B'0L?\)R_Y='^CO9%1\[^V<"\.^.R,56X'H/%Y.FTR[=ZT
MK=,6;[#2"IC\E/E>P9(C2XZ951TP4<DB/)!E"%+O>SG;ZVZ'*.W/6T@8-<$'
MXI1\,>.(CXL/]^$ @&/HV^[Q[>?N^R//.ZI2]N4*VJL/@A/Q2YX-+\*''Z0)
M!*R];4'O'[K*#KWOW7NO>_=>ZK(_FP? 3#?S /BON#8N/IJ.G[GZ_P#OM]]%
M[@G,-.8-Y4M"\=7M&OKG"O#MO?\ 01_858+B&&J%)6NLC4:(1Y[=\X2\G<P)
M=N2=KFI'.O\ 0)PX'\49[AYD:E%-1ZC7W4Y#AY]Y7DL8P!O%O66V<XI(!F,G
MR24=K>0;0Y!T =:;'\GSYX[@_ET_+RJV?VP^4VYTWV7F8^K^^MN9R.KH9-@;
MAQ.5J,;A]^5N,F\4E!E^O<Y)/39-)$,BXJIK4\;3I#HR;]RN48>=>6Q<[=I?
M<X%\6W9:'Q%8 M&#YB1:%?Z87-":X?>T7/5Q[>\VFSW75'L]R_@W2-4>$ZL0
MLI4\&B:H>HKH+BA8+0;O^%*<T-3_ ##MOU%/+%/3S_&OK":">&1989H9=S=B
MO%+%*A9)(I$8%6!((-Q[*?8T%>2W5A1A?2_\<BZ.OO'D-[@1LI!4[;#0_P"W
MFZVT?Y0O_;M+X<_^(@QW_NVR_O'7W)_Y7K<_^>D_X%ZRL]I?^G;[/_SR#_CS
M=6/^P1U(O7O?NO=5X?S$_P"6_P!(_P Q'JK^Z>_Z==L]F;7I,C-U1V]BJ..7
M<.R<M5Q:OLJ^+5 =Q;+R=5'&<ABI9$64*)()*>I6.=!IR5SONO)>X?4V9\2Q
MD(\:$GM<#S'\+@5TN!C@05J#'_N#[=;+[@[7])?CPMRB!,$ZCOC8^1X:XR::
MT)SQ4JP##0BWELKYH_R?_EO3M]WE>K^V-DU-1-M?>6&2?(;![1V94RQK+4XN
M:OI(<9O;8>XH%1:NBJH1)3S+XJF&GK(-,67UK=<K^Y7+APMQMTH&M&Q)$X\C
M0U21?)@:$94LIS@E>67.7M'S8,O:[K"3HD6IBGC/FM1IDB<4U*PJ#A@KKA1_
MS1?GKC?YB?;O3/>$6RY]@;GV]\<=J]7]B;<%6,AA(M\[?[)[7W%7U^T\@Y%;
M4[:RN(W=0U$*5*+44LLDE,[3^ 5,['('*#\E;;=;291-;O?/+&U*-X;10J X
MX!@48&F" &%*Z0H]SN>H_<+=K/>Q";>ZCVY(94K5?%2:=R8SQ*,LBD:LJ25.
MK3J;=Z_DF_\ ;KCXC?\ AH;R_P#?J[]]XJ>Z?_*_[E_S53_JU'UFK[+_ /3L
M=I_YHR?]7Y>M(G^<CA,I@/YF_P OZ/+T<U%4U79=/FZ>*9"C2XO<6T]MY[#5
MB7 U0UV*R,,R$<%7'O*KVRECFY#VUHR"H@*_FKLK#\B".L*_>"&6#W*W=)05
M8W(85_A>-&4_FI!ZW!_C7_.V_EJ_[+_TU1[I^1=#L+=&&ZTV5@-R;/W1LGL5
M<UM_.X+;F.Q64Q]3/B-HY7#UR15E(WCJ*2JGIYHR&5[W48U[[[5\\_OFZ:WL
MC-;M.[*Z/'I968D$5<,,'((!'677+GO3[<?N&S2ZW%8+I+:-7C>.74C*@5@2
ML;*<C!5B"//H;_\ A[+^5Q_WESM#_P! WM7_ .P+V4_ZUG/_ /T;9?\ >XO^
MMG1U_KT>V/\ T=H?^<<__6KKW_#V7\KC_O+G:'_H&]J__8%[]_K6<_\ _1ME
M_P![B_ZV=>_UZ/;'_H[0_P#..?\ ZU=1:W^=]_*RQ]+-63_+;;4D4 5G2BZ_
M[BR=4P9U0>&AQO7576U!NPN(XV(%R> 3[LGM3[@.P4;=)4^LD('[3( /V]5?
MWK]KXU+MNT=!Z17#']@B)/Y#JH;^8I_PHKZ9W%TYOWIOX6XS>FY-X]@[=RNT
M:SN/<^$EV=MS9V$SU-)C<MD=IX;)2+NO,;H?%SS1TDE52XV"@FDCJ :AHS"9
M(Y*]E-TAW.'<^:&B2VA<.(5;6SLIJ [#L5*TK0L6%5Q6O42^X7WA=FN-GGV?
MDU9I+RXC:,W#KX:1JPHQC4][/I)"EE0*2&[J:>JE?Y#/PMW=\F/FUL'MFHP]
M3'T]\8=PX?M3>&YI4,5'-OC"229/JW:6,F>.5*K-U6[:*GR4T8&F+&8ZH+/'
M))3B21O=WFBVV+E6;;E8?O._1HD7S\-L2N?10A*CU9A@@-2*/8ODV[YDYT@W
M5D/[HVR19Y'\O%7,$:^K&0!R/)$:I!*U.)_PHM_F*#MGLR#X0=4YT3==].YE
M<GW5DL;5,8-T]O4@EAI]F3-$!'48OK*"1A4IK96SD\L<D:RXZ-B&?93DK]W6
M!YKW%*7MRM( 1\$)XO\ (R^7_"P"#1ST+_O"^X7[UW(<E;4]=OLWU7!!P\XP
M(_FL(^+/]J2"*Q@]6M?\)_/Y=#?&'HA_DYVE@S2=Y_(?!T51@\=DJ0PY3KKI
MN6:/(X'#/'*/+29G?TL4&8R"DADI5Q].Z13P5"M'OO'SM^_MW_<.WO7:;)R&
M(.))N#-\UCRB_/602"O4I^PGMY_5G8_ZR[HE-[W! 5!%&BM^*K\FEQ(_HOAJ
M0&5J[#WN%^L@>O>_=>Z][]U[JEC^=Q_+J3YQ_&>?=G7V%%7\C.AJ3+;JZU%)
M%&M?O?;TB0S[QZPGDTEJF7,T5&*S$*URF8I8H5:**KJ7,H^U?.IY3WT6]XU-
MDO"$EKPC;\$ORTDT?^@2<E5'4->]/MZ.=N6S=;>E>8K$,\-.,B<9(3ZZ@-4?
M_#% ! =CUK:_R#/YA\OQ.^1+_'/M',O0=%_(G/8W#";*U$D%!USW&S1XC:^Y
MG\\@IL9BMU7CPV9=D0*?L:F:6.&ADU3C[P<ECF+9?WWMZUW:R0M@9DAXLOJ2
MGQI_MU )<=8Y^Q'N">5>8?ZN[F^G8]PD"]QH(;CX4?.%5\1R''X&)"H>M_'W
MA[UGCU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=1JVBH\C1U
M>/R%)35]!7TT]%74-;!%54=;1U4305-)5TTZO#44U1"[))&ZE74D$$'W969&
M#H2'!J",$$<"#Y$=5=$D0QR -&P(((J"#@@@\0?,=:E?\Q3_ (3@T^X,ANCN
M#X$Y/'X:OKI:[.9+XW;HK*?'8*6MGD-1-1]2[NJ6@HMOP2LQ\&'S#+10LQ$5
M?3P+%3)D7R5[W-"D>V\WJS(**+E!5J<*S(,M\W3N/FC&K'%+W"^[LMQ)+N_(
MC*DC$L;-R M3DB"0T"#TCD[1Y2*M%&I#V;U;V1TQO7-=<]L[&W1UUOO;M1]O
MF=J[PPU=@LU1,PUP3-1U\,,DU%60D2T]1'KIZF%EDB=XV5CD;8;A8[I:I>[=
M+'/:.*JZ,&4_F/,<"#D'! /6)^Y;7N.S7K[=NL$MO?1FC)(I5AZ&A\CQ!&",
M@D&O2"]J^D/7O?NO=>]^Z]U[W[KW7O?NO=+WJ[K#?O=/8>S^J>K]LY'>/8&_
M<Y1;<VIMO%K&:O*96N?3''Y9Y(:6CI8(U::HJ9Y(J>EIXWFF=(D=PDW"_L]K
MLI=QOY%BLX4+.QX #^9/D *DF@ )/2[:]LO]YW"':MLB::_G<(B+Q9C]M  .
M))("@$D@ GKZ0G\KK^6[L#^79T7!MF 8W<O=^^H<?F.Z.R(:="^5S,4 --M'
M;=3+3PUT&P]IM+(E%%)I>IJ'FK)%1Y_%%A#S]SQ><Z[L9SJCVJ$E8(J\%\W8
M5IXC_B(X"BBH%3T5]L?;JP]O=C%LNF7>IP&N)@/B:F(T- 1%'D*#Q)9R 6H+
M-_8#ZDKKWOW7NO>_=>Z(5_,?^"VT/Y@GQGW'TEG*VCVYN^CKZ/=W5>_*FD>K
M.R]]XE98J:KGAA*SU.$S>+JJG'9&%;EJ6J,B#SQ0.@OY(YMN>3=]3=8@7MB"
MDL8--<9XCY,I 93ZBAP2"!?<3D>TY^Y;DV6=A'=AA)!*17PY5X$TR5924<?P
MM4=P4C6]V9_PEJ[0AW=M>;?WR?Z[K-CPY_$3;PHML;2W1!N.MVS%7P29NBP5
M3D)A0TF6K,<LD=/-,&CAE9797"E3-]U[_P!@;:06=A.+LH=!=TTAJ=I8#) -
M"0,D8QUCI9_=AW,7<1O]SMS9"1?$"1N'*5&H*2:!B*@$X!S0\.MO!MG5&Q>I
MO[@='XS:FTZG:.PEVCU/BLO35YV5MF3"8$8?9E+D:+&L<E/MW"FFIQ+!"ZS2
MT\119%9M8QO^I6[W'ZS=FDD62;7,01K;4VIR"<:FJ:$X!-:>766GT;6.U?0;
M(L4310>' K ^&FE=,8(&2BT%0#4@4J#GK5\V+_PFHW?O+O%^X/EY\LJ/M"DS
M^_*_?79>$VCL_-4FX.R:O(Y$9G*4M=O7,;@IY< N?R,\RU<D%!--'3W6!HY'
M62">[OWSMK7:?W;RWMQMV2$1Q,[J5B &D$(J]VD4H"P!/$$"AQEL?NX7=YO?
M[WYMW47223F698XV#S$G4P,C.-.HDZB%) ^$@FJ[7&&PV)V[A\5M_ 8R@PN"
MP6-H<-A<-BJ2"@Q>)Q.,I8J+&XS&T-*D5-14%!1P)%#%&JI'&@50  />/,LL
MD\K33,7F=BS,34DDU)).22<DGB>LIX88K>%+>!52!%"JJ@!5510* ,  "@ P
M!TY>Z=.=>]^Z]U[W[KW7O?NO=:['\QK^0!LCYG][9+Y"=4]OTG1.[MZQP2]G
MX"MV(V[=L[HW#24\=(F\L8M!N3;=1@LYDJ6"-<E'IJ(:Z=?NB8ZAYVGFKDGW
MBN^5]H79MPMC=VT7]DPDT,BDUT&JL&4&NG@5';D 4Q[]P_86RYRWQN8-JNQ8
MW<P'C*8O$1W IXBT="K$ :QD,>[#%BQ+NTO^$ZGRW[QFZK/:'S#ZGR\O5?6&
MV>F<+G/[C[WKLVVP=I9G/U^W8*[[O*0QY.MV]C-P''TH\E.C45'3QL0RO*PH
MV_WJY<VD7'[OVRY47%PT[+KC"^(ZJ&I08#%=1P>YF/RZ!NZ?=ZYLWLVO[SW>
MT<VMLENK>'(6\*-G* U;)17T+D=JJ#FI.S;\1^@(?BO\:.EOCS#N63>7^B;8
MN*VG/NJ7&KAOX]74OEJ,CDX<0M7D/X92U-?4R&&G:HJ'AATJTLC NT$<Q[P>
M8-]NMZ,?A?4S%]%=6D' %:"I  J:"I\APZR5Y3V$<K\MV7+ZR&;Z2!8R]-.H
MC);34Z02305-!0$GCT8OV2="'KWOW7NO>_=>Z++\JOA]\>_FCUQ+UA\ANO\
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MZ57B: DGT  !))(  ))IUK==VV[8["3=-VF2"PB +.W 5( &*DDD@  $DD
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M,Y\(_P#LHS^9Y_XM_M3_ .!>Z']D/-7_ "1-A_Z5K_\ :5<=";DO_E8>9O\
MI;I_VA6O2*_EXTL,7PV[Z6EIHHWJ?DG\^&D6GA5&GF7Y ]L4L3.(U!ED6G@C
MC4FY"(JC@ >U7.C$\S6>HX%CM_\ VCPG_9Z1>WR <GWX4"IW+=.'G_C4X_P
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M_P !SVW[0<N_\JGS#_SS6G_:;#T9<U?\KORM_P ]=[_W;Y^O?S9O^R&M^?\
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(7NO>_=>Z_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140095980999696">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover Page<br></strong></div></th>
<th class="th"><div>Nov. 02, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">VANDA PHARMACEUTICALS INC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-34186<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">03-0491827<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2200 Pennsylvania Avenue NW<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 300E<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Washington<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">DC<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">20037<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">202<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">734-3400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">VNDA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001347178<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov.  02,  2022<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>vnda-20221102_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="vnda-20221102.xsd" xlink:type="simple"/>
    <context id="i55a4437699c64486a93ad70857fc2bf4_D20221102-20221102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
        </entity>
        <period>
            <startDate>2022-11-02</startDate>
            <endDate>2022-11-02</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="i55a4437699c64486a93ad70857fc2bf4_D20221102-20221102"
      id="id3VybDovL2RvY3MudjEvZG9jOjZhZGE0Yzc3NWRiZTQ0NDViNjg3OTFkYmZiOGRkOTJmL3NlYzo2YWRhNGM3NzVkYmU0NDQ1YjY4NzkxZGJmYjhkZDkyZl80L2ZyYWc6ZTAxM2MxZDE2NTE0NGVkOWIxNDlhOWVmMjg3MWQ1NjYvdGFibGU6MWM5MTU1MGE0N2Y3NDQ4OGFmODE5ZDUxN2ZkYWI2ZTQvdGFibGVyYW5nZToxYzkxNTUwYTQ3Zjc0NDg4YWY4MTlkNTE3ZmRhYjZlNF8yLTEtMS0xLTQyOTA2_d468cffe-3ad9-4c3e-8df6-6b9f2df28d94">0001347178</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="i55a4437699c64486a93ad70857fc2bf4_D20221102-20221102"
      id="id3VybDovL2RvY3MudjEvZG9jOjZhZGE0Yzc3NWRiZTQ0NDViNjg3OTFkYmZiOGRkOTJmL3NlYzo2YWRhNGM3NzVkYmU0NDQ1YjY4NzkxZGJmYjhkZDkyZl80L2ZyYWc6ZTAxM2MxZDE2NTE0NGVkOWIxNDlhOWVmMjg3MWQ1NjYvdGFibGU6MWM5MTU1MGE0N2Y3NDQ4OGFmODE5ZDUxN2ZkYWI2ZTQvdGFibGVyYW5nZToxYzkxNTUwYTQ3Zjc0NDg4YWY4MTlkNTE3ZmRhYjZlNF8zLTEtMS0xLTQyOTA2_4192f358-beaa-4c18-a0cb-4c0b1c033740">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="i55a4437699c64486a93ad70857fc2bf4_D20221102-20221102"
      id="id3VybDovL2RvY3MudjEvZG9jOjZhZGE0Yzc3NWRiZTQ0NDViNjg3OTFkYmZiOGRkOTJmL3NlYzo2YWRhNGM3NzVkYmU0NDQ1YjY4NzkxZGJmYjhkZDkyZl8xL2ZyYWc6MTdkYjhhNDNjNzIyNDM5YTkwM2YwZWE1ZDBlZTliNDYvdGV4dHJlZ2lvbjoxN2RiOGE0M2M3MjI0MzlhOTAzZjBlYTVkMGVlOWI0Nl8xMzEy_076364d8-0857-4df4-b30e-62f224b2b871">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="i55a4437699c64486a93ad70857fc2bf4_D20221102-20221102"
      id="id3VybDovL2RvY3MudjEvZG9jOjZhZGE0Yzc3NWRiZTQ0NDViNjg3OTFkYmZiOGRkOTJmL3NlYzo2YWRhNGM3NzVkYmU0NDQ1YjY4NzkxZGJmYjhkZDkyZl8xL2ZyYWc6MTdkYjhhNDNjNzIyNDM5YTkwM2YwZWE1ZDBlZTliNDYvdGV4dHJlZ2lvbjoxN2RiOGE0M2M3MjI0MzlhOTAzZjBlYTVkMGVlOWI0Nl8yMzM_664cc677-b6e1-433c-a569-a0ee8bebc375">2022-11-02</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="i55a4437699c64486a93ad70857fc2bf4_D20221102-20221102"
      id="id3VybDovL2RvY3MudjEvZG9jOjZhZGE0Yzc3NWRiZTQ0NDViNjg3OTFkYmZiOGRkOTJmL3NlYzo2YWRhNGM3NzVkYmU0NDQ1YjY4NzkxZGJmYjhkZDkyZl8xL2ZyYWc6MTdkYjhhNDNjNzIyNDM5YTkwM2YwZWE1ZDBlZTliNDYvdGV4dHJlZ2lvbjoxN2RiOGE0M2M3MjI0MzlhOTAzZjBlYTVkMGVlOWI0Nl8xMzA1_7887b672-b28c-49c8-81d0-e933c6b107b1">VANDA PHARMACEUTICALS INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i55a4437699c64486a93ad70857fc2bf4_D20221102-20221102"
      id="id3VybDovL2RvY3MudjEvZG9jOjZhZGE0Yzc3NWRiZTQ0NDViNjg3OTFkYmZiOGRkOTJmL3NlYzo2YWRhNGM3NzVkYmU0NDQ1YjY4NzkxZGJmYjhkZDkyZl8xL2ZyYWc6MTdkYjhhNDNjNzIyNDM5YTkwM2YwZWE1ZDBlZTliNDYvdGFibGU6MDhiYThlMDc1ZmI0NDAzYmJlMTdhNjZjYTg1N2UwZWYvdGFibGVyYW5nZTowOGJhOGUwNzVmYjQ0MDNiYmUxN2E2NmNhODU3ZTBlZl8wLTAtMS0xLTQyOTA2_b5093353-3e29-4a69-8e68-17ecb12d4855">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="i55a4437699c64486a93ad70857fc2bf4_D20221102-20221102"
      id="id3VybDovL2RvY3MudjEvZG9jOjZhZGE0Yzc3NWRiZTQ0NDViNjg3OTFkYmZiOGRkOTJmL3NlYzo2YWRhNGM3NzVkYmU0NDQ1YjY4NzkxZGJmYjhkZDkyZl8xL2ZyYWc6MTdkYjhhNDNjNzIyNDM5YTkwM2YwZWE1ZDBlZTliNDYvdGFibGU6MDhiYThlMDc1ZmI0NDAzYmJlMTdhNjZjYTg1N2UwZWYvdGFibGVyYW5nZTowOGJhOGUwNzVmYjQ0MDNiYmUxN2E2NmNhODU3ZTBlZl8wLTItMS0xLTQyOTA2_edd4a516-d39f-4628-bed3-e68dd9e5bd13">001-34186</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="i55a4437699c64486a93ad70857fc2bf4_D20221102-20221102"
      id="id3VybDovL2RvY3MudjEvZG9jOjZhZGE0Yzc3NWRiZTQ0NDViNjg3OTFkYmZiOGRkOTJmL3NlYzo2YWRhNGM3NzVkYmU0NDQ1YjY4NzkxZGJmYjhkZDkyZl8xL2ZyYWc6MTdkYjhhNDNjNzIyNDM5YTkwM2YwZWE1ZDBlZTliNDYvdGFibGU6MDhiYThlMDc1ZmI0NDAzYmJlMTdhNjZjYTg1N2UwZWYvdGFibGVyYW5nZTowOGJhOGUwNzVmYjQ0MDNiYmUxN2E2NmNhODU3ZTBlZl8wLTQtMS0xLTQyOTA2_3b13b24b-9cee-4f48-98b6-75a0fe989d57">03-0491827</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i55a4437699c64486a93ad70857fc2bf4_D20221102-20221102"
      id="id3VybDovL2RvY3MudjEvZG9jOjZhZGE0Yzc3NWRiZTQ0NDViNjg3OTFkYmZiOGRkOTJmL3NlYzo2YWRhNGM3NzVkYmU0NDQ1YjY4NzkxZGJmYjhkZDkyZl8xL2ZyYWc6MTdkYjhhNDNjNzIyNDM5YTkwM2YwZWE1ZDBlZTliNDYvdGV4dHJlZ2lvbjoxN2RiOGE0M2M3MjI0MzlhOTAzZjBlYTVkMGVlOWI0Nl8xMzA2_ffc2923d-0a96-4be3-8573-29f4ab734036">2200 Pennsylvania Avenue NW</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="i55a4437699c64486a93ad70857fc2bf4_D20221102-20221102"
      id="id3VybDovL2RvY3MudjEvZG9jOjZhZGE0Yzc3NWRiZTQ0NDViNjg3OTFkYmZiOGRkOTJmL3NlYzo2YWRhNGM3NzVkYmU0NDQ1YjY4NzkxZGJmYjhkZDkyZl8xL2ZyYWc6MTdkYjhhNDNjNzIyNDM5YTkwM2YwZWE1ZDBlZTliNDYvdGV4dHJlZ2lvbjoxN2RiOGE0M2M3MjI0MzlhOTAzZjBlYTVkMGVlOWI0Nl8xMzA3_691b3879-c7c8-4c47-8c5b-dcd4f29273fe">Suite 300E</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="i55a4437699c64486a93ad70857fc2bf4_D20221102-20221102"
      id="id3VybDovL2RvY3MudjEvZG9jOjZhZGE0Yzc3NWRiZTQ0NDViNjg3OTFkYmZiOGRkOTJmL3NlYzo2YWRhNGM3NzVkYmU0NDQ1YjY4NzkxZGJmYjhkZDkyZl8xL2ZyYWc6MTdkYjhhNDNjNzIyNDM5YTkwM2YwZWE1ZDBlZTliNDYvdGV4dHJlZ2lvbjoxN2RiOGE0M2M3MjI0MzlhOTAzZjBlYTVkMGVlOWI0Nl8xMzA4_72f2c2af-b973-416a-890e-41c6ae3cf284">Washington</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i55a4437699c64486a93ad70857fc2bf4_D20221102-20221102"
      id="id3VybDovL2RvY3MudjEvZG9jOjZhZGE0Yzc3NWRiZTQ0NDViNjg3OTFkYmZiOGRkOTJmL3NlYzo2YWRhNGM3NzVkYmU0NDQ1YjY4NzkxZGJmYjhkZDkyZl8xL2ZyYWc6MTdkYjhhNDNjNzIyNDM5YTkwM2YwZWE1ZDBlZTliNDYvdGV4dHJlZ2lvbjoxN2RiOGE0M2M3MjI0MzlhOTAzZjBlYTVkMGVlOWI0Nl8xMzA5_db53dd2d-2eaa-4a9b-b587-5e882308478b">DC</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i55a4437699c64486a93ad70857fc2bf4_D20221102-20221102"
      id="id3VybDovL2RvY3MudjEvZG9jOjZhZGE0Yzc3NWRiZTQ0NDViNjg3OTFkYmZiOGRkOTJmL3NlYzo2YWRhNGM3NzVkYmU0NDQ1YjY4NzkxZGJmYjhkZDkyZl8xL2ZyYWc6MTdkYjhhNDNjNzIyNDM5YTkwM2YwZWE1ZDBlZTliNDYvdGV4dHJlZ2lvbjoxN2RiOGE0M2M3MjI0MzlhOTAzZjBlYTVkMGVlOWI0Nl8zNzk_89f5ab37-d9a9-4e00-8bac-1473e5a7e6ef">20037</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i55a4437699c64486a93ad70857fc2bf4_D20221102-20221102"
      id="id3VybDovL2RvY3MudjEvZG9jOjZhZGE0Yzc3NWRiZTQ0NDViNjg3OTFkYmZiOGRkOTJmL3NlYzo2YWRhNGM3NzVkYmU0NDQ1YjY4NzkxZGJmYjhkZDkyZl8xL2ZyYWc6MTdkYjhhNDNjNzIyNDM5YTkwM2YwZWE1ZDBlZTliNDYvdGV4dHJlZ2lvbjoxN2RiOGE0M2M3MjI0MzlhOTAzZjBlYTVkMGVlOWI0Nl80ODk_ec439f44-5e00-448e-b2d4-1c46a1f2224e">202</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i55a4437699c64486a93ad70857fc2bf4_D20221102-20221102"
      id="id3VybDovL2RvY3MudjEvZG9jOjZhZGE0Yzc3NWRiZTQ0NDViNjg3OTFkYmZiOGRkOTJmL3NlYzo2YWRhNGM3NzVkYmU0NDQ1YjY4NzkxZGJmYjhkZDkyZl8xL2ZyYWc6MTdkYjhhNDNjNzIyNDM5YTkwM2YwZWE1ZDBlZTliNDYvdGV4dHJlZ2lvbjoxN2RiOGE0M2M3MjI0MzlhOTAzZjBlYTVkMGVlOWI0Nl8xMzEw_434ce63e-dc4e-4dfe-951b-c32812917c8a">734-3400</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="i55a4437699c64486a93ad70857fc2bf4_D20221102-20221102"
      id="id3VybDovL2RvY3MudjEvZG9jOjZhZGE0Yzc3NWRiZTQ0NDViNjg3OTFkYmZiOGRkOTJmL3NlYzo2YWRhNGM3NzVkYmU0NDQ1YjY4NzkxZGJmYjhkZDkyZl8xL2ZyYWc6MTdkYjhhNDNjNzIyNDM5YTkwM2YwZWE1ZDBlZTliNDYvdGFibGU6NDgzMTMxZTNhMjBkNDc2MmIxY2UzYWJjOGY1YTE1OGIvdGFibGVyYW5nZTo0ODMxMzFlM2EyMGQ0NzYyYjFjZTNhYmM4ZjVhMTU4Yl8wLTAtMS0xLTQyOTA2_f4968d31-bcef-43c5-9b59-c6e11ffc9cd9">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="i55a4437699c64486a93ad70857fc2bf4_D20221102-20221102"
      id="id3VybDovL2RvY3MudjEvZG9jOjZhZGE0Yzc3NWRiZTQ0NDViNjg3OTFkYmZiOGRkOTJmL3NlYzo2YWRhNGM3NzVkYmU0NDQ1YjY4NzkxZGJmYjhkZDkyZl8xL2ZyYWc6MTdkYjhhNDNjNzIyNDM5YTkwM2YwZWE1ZDBlZTliNDYvdGFibGU6NDgzMTMxZTNhMjBkNDc2MmIxY2UzYWJjOGY1YTE1OGIvdGFibGVyYW5nZTo0ODMxMzFlM2EyMGQ0NzYyYjFjZTNhYmM4ZjVhMTU4Yl8yLTAtMS0xLTQyOTA2_2c058764-68ca-4017-aca4-f93962c9567e">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="i55a4437699c64486a93ad70857fc2bf4_D20221102-20221102"
      id="id3VybDovL2RvY3MudjEvZG9jOjZhZGE0Yzc3NWRiZTQ0NDViNjg3OTFkYmZiOGRkOTJmL3NlYzo2YWRhNGM3NzVkYmU0NDQ1YjY4NzkxZGJmYjhkZDkyZl8xL2ZyYWc6MTdkYjhhNDNjNzIyNDM5YTkwM2YwZWE1ZDBlZTliNDYvdGFibGU6NDgzMTMxZTNhMjBkNDc2MmIxY2UzYWJjOGY1YTE1OGIvdGFibGVyYW5nZTo0ODMxMzFlM2EyMGQ0NzYyYjFjZTNhYmM4ZjVhMTU4Yl80LTAtMS0xLTQyOTA2_f884c670-d45a-43b4-b1b8-d860cb8c4974">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="i55a4437699c64486a93ad70857fc2bf4_D20221102-20221102"
      id="id3VybDovL2RvY3MudjEvZG9jOjZhZGE0Yzc3NWRiZTQ0NDViNjg3OTFkYmZiOGRkOTJmL3NlYzo2YWRhNGM3NzVkYmU0NDQ1YjY4NzkxZGJmYjhkZDkyZl8xL2ZyYWc6MTdkYjhhNDNjNzIyNDM5YTkwM2YwZWE1ZDBlZTliNDYvdGFibGU6NDgzMTMxZTNhMjBkNDc2MmIxY2UzYWJjOGY1YTE1OGIvdGFibGVyYW5nZTo0ODMxMzFlM2EyMGQ0NzYyYjFjZTNhYmM4ZjVhMTU4Yl82LTAtMS0xLTQyOTA2_eccdcbf8-fe0c-4212-a0c7-e6db74af7bf3">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="i55a4437699c64486a93ad70857fc2bf4_D20221102-20221102"
      id="id3VybDovL2RvY3MudjEvZG9jOjZhZGE0Yzc3NWRiZTQ0NDViNjg3OTFkYmZiOGRkOTJmL3NlYzo2YWRhNGM3NzVkYmU0NDQ1YjY4NzkxZGJmYjhkZDkyZl8xL2ZyYWc6MTdkYjhhNDNjNzIyNDM5YTkwM2YwZWE1ZDBlZTliNDYvdGFibGU6MmNmZTMxMTVjN2FjNDk4MGIxNmM3NjMxZjI2ZjU3OWMvdGFibGVyYW5nZToyY2ZlMzExNWM3YWM0OTgwYjE2Yzc2MzFmMjZmNTc5Y18xLTAtMS0xLTQyOTA2_f64059cf-8c2a-47f4-906c-be49a6bd067b">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i55a4437699c64486a93ad70857fc2bf4_D20221102-20221102"
      id="id3VybDovL2RvY3MudjEvZG9jOjZhZGE0Yzc3NWRiZTQ0NDViNjg3OTFkYmZiOGRkOTJmL3NlYzo2YWRhNGM3NzVkYmU0NDQ1YjY4NzkxZGJmYjhkZDkyZl8xL2ZyYWc6MTdkYjhhNDNjNzIyNDM5YTkwM2YwZWE1ZDBlZTliNDYvdGFibGU6MmNmZTMxMTVjN2FjNDk4MGIxNmM3NjMxZjI2ZjU3OWMvdGFibGVyYW5nZToyY2ZlMzExNWM3YWM0OTgwYjE2Yzc2MzFmMjZmNTc5Y18xLTEtMS0xLTQyOTA2_85768338-3c23-419b-a9d2-3fff31ad26e5">VNDA</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i55a4437699c64486a93ad70857fc2bf4_D20221102-20221102"
      id="id3VybDovL2RvY3MudjEvZG9jOjZhZGE0Yzc3NWRiZTQ0NDViNjg3OTFkYmZiOGRkOTJmL3NlYzo2YWRhNGM3NzVkYmU0NDQ1YjY4NzkxZGJmYjhkZDkyZl8xL2ZyYWc6MTdkYjhhNDNjNzIyNDM5YTkwM2YwZWE1ZDBlZTliNDYvdGFibGU6MmNmZTMxMTVjN2FjNDk4MGIxNmM3NjMxZjI2ZjU3OWMvdGFibGVyYW5nZToyY2ZlMzExNWM3YWM0OTgwYjE2Yzc2MzFmMjZmNTc5Y18xLTItMS0xLTQyOTA2_a372827c-11d1-4687-b35f-7a3cc4c377eb">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="i55a4437699c64486a93ad70857fc2bf4_D20221102-20221102"
      id="id3VybDovL2RvY3MudjEvZG9jOjZhZGE0Yzc3NWRiZTQ0NDViNjg3OTFkYmZiOGRkOTJmL3NlYzo2YWRhNGM3NzVkYmU0NDQ1YjY4NzkxZGJmYjhkZDkyZl8xL2ZyYWc6MTdkYjhhNDNjNzIyNDM5YTkwM2YwZWE1ZDBlZTliNDYvdGV4dHJlZ2lvbjoxN2RiOGE0M2M3MjI0MzlhOTAzZjBlYTVkMGVlOWI0Nl8xMzEz_0a4b47ee-bcd7-490a-9afa-1a2c79a67e6b">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M#RP/9'I;K?%NXQ/R^AQ@/7UM0K"=XI.([12O-2#QNH%'GL>[C>4!#ZP+V.Q
M_G@>F*FX3YI"5S%NV G&D3S'$)C%^(QF&5*=##[Q_F"G)$WS/(X %F>0IA@"
MIQ%', ;  4/2='@//GL?)=-[*CG_5U/\!%!+ P04    "  ,@6)5EXJ[',
M   3 @  "P   %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">, ?0(8@S9?$6!/D!
M5J(/V!(%BD6=OZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]$%)I6M6X 4BV)8]I
MSI%"KM0L'C6'TD!$VV-#L%HL/D N&6:WO606IW.D5XA<UYVE/=LO3T%O@*\Z
M3'%":4A+,P[PS=)_,O?S##5%Y4HCE5L:>-/E_G;@2=&A(E@6FD7)TZ(=I7\=
MQ_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0    (  R!
M8E49117U-P$  "<"   /    >&PO=V]R:V)O;VLN>&ULC5'1;L(P#/R5*A^P
M%K0A#5%>0-N0I@V-B??0NM0BB2O'A8VOG]NJ&M)>]I3<V;K<7187XM.!Z)1\
M>1=B;FJ19IZFL:C!VWA'#02=5,3>BD(^IK%AL&6L <2[=)IEL]1;#&:Y&+6V
MG-X"$B@$*2C9$7N$2_R==S Y8\0#.I3OW/1W!R;Q&-#C%<K<9":)-5U>B/%*
M0:S;%4S.Y68R#/; @L4?>M>9_+2'V#-B#Q]6C>1FEJE@A1REW^CUK7H\@RX/
MJ!5Z0B? :ROPS-0V&(Z=C*9(;V+T/8SG4.*<_U,C5146L*:B]1!DZ)'!=09#
MK+&))@G60VY6= 9.MO8(72A]95,. 46=W=3%<]0!;\K!XVBLA H#E&^J%977
MDHHM)]W1ZTSO'R:/6D;KW$JY]_!*MAQSCG^T_ %02P,$%     @ #(%B520>
MFZ*M    ^ $  !H   !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<[61/0Z#
M, R%KQ+E #50J4,%3%U8*RX0!?,C$A+%K@JW+X4!D#IT8;*>+7_OR4Z?:!1W
M;J"V\R1&:P;*9,OL[P"D6[2*+L[C,$]J%ZSB688&O-*]:A"2*+I!V#-DGNZ9
MHIP\_D-T==UI?#C]LCCP#S"\7>BI160I2A4:Y$S":+8VP5+BRTR6HJ@R&8HJ
MEG!:(.+)(&UI5GVP3TZTYWD7-_=%KLWC":[?#'!X=/X!4$L#!!0    (  R!
M8E5ED'F2&0$  ,\#   3    6T-O;G1E;G1?5'EP97-=+GAM;*V334[#,!"%
MKQ)E6R4N+%B@IAM@"UUP 6-/&JO^DV=:TMLS3MI*H!(5A4VL>-Z\SYZ7K-Z/
M$;#HG?78E!U1?!0"50=.8ATB>*ZT(3E)_)JV(DJUDUL0]\OE@U#!$WBJ*'N4
MZ]4SM')OJ7CI>1M-\$V9P&)9/(W"S&I*&:,U2A+7Q<'K'Y3J1*BY<]!@9R(N
M6%"*JX1<^1UPZGL[0$I&0[&1B5ZE8Y7HK4 Z6L!ZVN+*&4/;&@4ZJ+WCEAIC
M JFQ R!GZ]%T,4TFGC",S[O9_,%F"LC*30H1.;$$?\>=(\G=560C2&2FKW@A
MLO7L^T%.6X.^D<WC_0QI-^2!8ECFS_A[QA?_&\[Q$<+NOS^QO-9.&G_FB^$_
M7G\!4$L! A0#%     @ #(%B50=!36*!    L0   !               ( !
M     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    "  ,@6)5)&;I2>X    K
M @  $0              @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4
M    "  ,@6)5F5R<(Q &  "<)P  $P              @ ', 0  >&PO=&AE
M;64O=&AE;64Q+GAM;%!+ 0(4 Q0    (  R!8E5"%IZ%<@0  #01   8
M          " @0T(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4
M    "  ,@6)5GZ ;\+$"  #B#   #0              @ &U#   >&PO<W1Y
M;&5S+GAM;%!+ 0(4 Q0    (  R!8E67BKL<P    !,"   +
M  "  9$/  !?<F5L<R\N<F5L<U!+ 0(4 Q0    (  R!8E49117U-P$  "<"
M   /              "  7H0  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4
M"  ,@6)5)!Z;HJT   #X 0  &@              @ '>$0  >&PO7W)E;',O
M=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    "  ,@6)599!YDAD!  #/ P
M$P              @ '#$@  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08
.."0 ) #X"   -%      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="vnda-20221102.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="vnda-20221102.htm">vnda-20221102.htm</File>
    <File>vnda-20221102.xsd</File>
    <File>vnda-20221102_lab.xml</File>
    <File>vnda-20221102_pre.xml</File>
    <File>vnda8-k1122022exhibit991.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "vnda-20221102.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "vnda-20221102.htm"
     ]
    },
    "labelLink": {
     "local": [
      "vnda-20221102_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "vnda-20221102_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "vnda-20221102.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 24,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021q4": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 23,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "vnda",
   "nsuri": "http://www.vandapharmaceuticals.com/20221102",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda-20221102.htm",
      "contextRef": "i55a4437699c64486a93ad70857fc2bf4_D20221102-20221102",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover Page",
     "role": "http://www.vandapharmaceuticals.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda-20221102.htm",
      "contextRef": "i55a4437699c64486a93ad70857fc2bf4_D20221102-20221102",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001628280-22-027812-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-22-027812-xbrl.zip
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M3,)!68.:>!<P\;V+H.P 3UD$%2;$]MFDO!U&T!7LA+Y/!C$K3_[X/+%BF;>
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ML=GR"&QO/IO']U;N3XWK7@C&GK\HWF]63GXQ)^:('Z.RYISF;73&G03TK4O
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M]RZ9/UY^>N7Y*R6OPM2?T<3YFK]P%E[D&!.P"Y+OK^>_>8C&HGXV'C$PU">
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MZRRUL&ER=<V2?9KZXVQ5 <WRQ%&6'\XF:6(8GVS"86["*9]&$G8G+\#SQ&G
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MY^.J6W(+^0/1Z,Z;<CCO(.M=6FOLNMING=]?N_WSB]5TAOW.+T;/4$L#!!0
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M$K)[YB4PAP<6,O)#HUZM$9B:"V)A"3!M%2QS]V3' 74[#B#ND;C/2)>'44R
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MAQ+L..2RBN-'$[K-G[]_JYB-.BJF&"^_YUB4'_E8*/GNK6&>@B0!Y7B Q<J
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M.-]O)NLQ@[Y)D-5^"$+7\X5L#:GTWWK(!'N &MZHV#P3_^CL'BF\D>@89?.
MIOW"Y%HS[R\0E@L@=N IA6 .*^%=G!4J)+'4'+);E.&K'N7CLB=S/]>.#)N=
M8(-HH<N@2P+FPD 3P8HCU,S%NY_4L&9Z/C*/,LPW;1@H/!X #%0)A86%T[A/
M'2E"R9I6I>3TJ9C.!)\8*B.C(V 489MR&TQ"X7(6FE.N^56*4:FBVZ:)B!B
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MGI<)E&W3H#MD^((D4*T5/4$E?(L/7ZUI*9:ZK$)6 GAG *RKJM)H+&L7O1:
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M,#(R,3$P,E]P<F4N>&UL4$L! A0#%     @ #(%B58X"Q(=K)   WM,! !P
M             ( !32\  '9N9&$X+6LQ,3(R,#(R97AH:6)I=#DY,2YH=&U0
52P4&      4 !0!. 0  \E,

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
